Hutchison China Meditech Limited Appointment of Director (4095T)
October 12 2017 - 1:30AM
UK Regulatory
TIDMHCM
RNS Number : 4095T
Hutchison China Meditech Limited
12 October 2017
Appointment of Director
London: Thursday, October 12, 2017: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that
Professor Mok, Shu Kam Tony has been appointed as Independent
Non-Executive Director and member of the Technical Committee with
effect from October 12, 2017.
Professor Mok, aged 57, has more than 30 years of experience in
clinical oncology with his main research interest focusing on
biomarker and molecular targeted therapy in lung cancer. He is
currently Li Shu Fan Medical Foundation Named Professor and
Chairman of Department of Clinical Oncology at The Chinese
University of Hong Kong. He co-founded the Lung Cancer Research
Group and has led a number of important multinational clinical
trials, which include the IPASS, FASTAST 2, IMPRESS and PROFILE
1014 that contributed to the current standard of practice on
management of advanced stage lung cancer.
Professor Mok has contributed to over 200 articles in
international peer-reviewed journals, including the New England
Journal of Medicine, Science, Lancet and Journal of Clinical
Oncology, and contributed to multiple editorials and textbooks. He
is Past Chair of the American Society of Clinical Oncology (ASCO)
International Affairs Committee, a member of the ASCO Publications
Committee and Vice Secretary of the Chinese Society of Clinical
Oncology (CSCO).
Professor Mok is closely affiliated with the oncology community
in China and has been awarded an Honorary Professorship at
Guangdong Province People's Hospital, Guest Professorship at Peking
University School of Oncology and Visiting Professorship at
Shanghai Jiao Tong University and West China School of
Medicine/West China Hospital, Sichuan University.
He received his Bachelor of Medical Science degree and Doctor of
Medicine from University of Alberta, Canada. He is also a Fellow of
Royal College of Physicians and Surgeons of Canada, Hong Kong
College of Physicians, Hong Kong Academy of Medicine, Royal College
of Physicians of Edinburgh and American Society of Clinical
Oncology.
Professor Mok is currently a member of the board of directors of
Sanomics Limited, the Chinese Lung Cancer Research Fund and the
International Association for the Study of Lung Cancer (ISALC). He
is also Chairman of The Hong Kong Cancer Therapy Society.
Professor Mok holds 10,002 American Depositary Shares of Chi-Med
(each representing one half of one ordinary share of US$1.00 each
in the capital of Chi-Med), representing approximately 0.008% of
the current issued share capital of Chi-Med. Save for the
information disclosed above, there is no other information in
relation to Professor Mok that is required to be disclosed pursuant
to Rule 17 and Schedule 2(g) of the AIM Rules for Companies.
Mr Simon To, Chairman of Chi-Med said, "We welcome Professor Mok
to the Board. His renowned expertise and extensive experience in
clinical oncology, with particular emphasis in lung cancer, will be
important to the Company."
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 0001). For more information,
please visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee,
SVP Corporate Finance & Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAFFDSMEFWSEFS
(END) Dow Jones Newswires
October 12, 2017 02:30 ET (06:30 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2023 to Apr 2024